A. Carr

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship.

P. Vanhems, B. Hirschel, D. Cooper, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hip Structural Parameters over 96 Weeks in HIV-Infected Adults Switching Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

Dominic Michael Dwyer, S. Emery, J. Amin, 2014, PloS one.

Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine

S. Emery, J. Amin, P. Ebeling, 2012, PloS one.

Review A new era of antiretroviral drug toxicity

B. Hirschel, D. Cooper, A. Calmy, 2009 .

A new era of antiretroviral drug toxicity

B. Hirschel, D. Cooper, A. Calmy, 2008, Antiviral therapy.

Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy

J. Lundgren, R. Weber, A. Copas, 2007, AIDS.

HIV‐associated lipodystrophy

D. Cooper, P. Mallon, A. Carr, 2001, HIV medicine.

Adherence to HIV Treatment Guidelines for Comorbid Disease Assessment and Initiation of Antiretroviral Therapy

M. Bailey, M. Bloch, J. Hoy, 2012, Journal of acquired immune deficiency syndromes.

Nucleoside reverse transcriptase inhibitor‐reducing strategies in HIV treatment: assessing the evidence

A. Antinori, C. Orkin, S. Gallien, 2018, HIV medicine.

Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial

K. Ensrud, J. Shepherd, A. Schwartz, 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Post-prandial lipid effects of raltegravir versus darunavir/ritonavir in HIV-1-infected adults commencing combination ART.

D. Marriott, M. Bloch, A. Carr, 2016, The Journal of antimicrobial chemotherapy.

Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up

J. Amin, A. Carr, F. Lee, 2014, PloS one.

A Meta-Analysis of Six Placebo-Controlled Trials of Thiazolidinedione Therapy for HIV Lipoatrophy

H. Wand, W. Rozenbaum, D. Costagliola, 2010, HIV clinical trials.

Clinical update: adverse effects of antiretroviral therapy

B. Hirschel, D. Cooper, A. Calmy, 2007, The Lancet.

Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?

A. Carr, 2004, The Lancet.

Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.

D. Cooper, M. Law, J. Amin, 2002, JAMA.

HIV nucleoside analogues: new adverse effects on mitochondria?

A. Carr, Andrew AM Mor ris, 1999, The Lancet.

Risk factors for fatality in HIV-infected patients with NRTI-induced severe hyperlactataemia or lactic acidosis

R. Weber, A. Copas, P. Reiss, 2012 .

Risk Factors for Fatality in HIV-Infected Patients with Dideoxynucleoside-Induced Severe Hyperlactataemia or Lactic Acidosis

R. Weber, A. Copas, P. Reiss, 2011, Antiviral Therapy.

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

D. Cooper, A. Kelleher, S. Emery, 2010, AIDS.

HIV Protease Inhibitor-induced Lipodystrophy Syndrome

A. Carr, 2001 .

Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy *

D. Cooper, H. Wand, M. Law, 2008, HIV medicine.

High reproducibility of histological diagnosis of human papillomavirus-related intraepithelial lesions of the anal canal

S. Garland, S. Tabrizi, C. Fairley, 2015, Pathology.

HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management

A. Carr, 2003, AIDS.

Successful lymphoablative autologous haematopoietic stem cell transplantation in three cases of severe autoimmune disease despite reduced dose cyclophosphamide conditioning—do we need 200 mg/kg cyclophosphamide?

D. Ma, J. Moore, A. Carr, 2022, Bone Marrow Transplantation.

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial

D. Cooper, H. Wand, M. Law, 2004, The Lancet.

Postprandial lipid effects of low-dose ritonavir vs. raltegravir in HIV-uninfected adults

K. Samaras, A. Carr, R. Richardson, 2010, AIDS.

In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA.

D. Cooper, A. Kelleher, D. Chisholm, 2005, The Journal of infectious diseases.

Centralized Assessment of Dual-Energy X-ray Absorptiometry (DEXA) in Multicenter Studies of HIV-Associated Lipodystrophy

D. Cooper, M. Law, Allison Martin, 2003, HIV clinical trials.

Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy

A. Winston, D. Cooper, D. Marriott, 2006, HIV medicine.

HIV lipodystrophy: prevalence, severity and correlates of risk in Australia

S. Mallal, J. Kaldor, D. Cooper, 2003, HIV medicine.

HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.

G. Moyle, A. Carr, 2002, HIV clinical trials.

Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine

D. Cooper, S. Emery, J. Amin, 2011, PloS one.

Is screening for sexually transmitted infections in men who have sex with men who receive non-occupational HIV post-exposure prophylaxis worthwhile?

A. Winston, D. Cooper, J. Amin, 2006, Sexually Transmitted Infections.

Sex differences in the associations of HIV disease characteristics and body composition in antiretroviral-naive persons.

Jack Wang, W. El-Sadr, C. Grunfeld, 2005, The American journal of clinical nutrition.

Safety and immunogenicity of UBI HIV-1MN octameric V3 peptide vaccine administered by subcutaneous injection.

D. Cooper, C. Duncombe, A. Kelleher, 1997, AIDS research and human retroviruses.

The rate of bone loss slows after 1–2 years of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (START) bone mineral density substudy

K. Ensrud, A. Schwartz, B. Grund, 2020, HIV medicine.

Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men—a randomized, placebo-controlled study

D. Cooper, J. Kovacic, M. Feneley, 2006, AIDS.

Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals.

G. Stewart, S. Emery, P. Williamson, 2003, Clinical immunology.

Lipodystrophy Associated with an HIV-Protease Inhibitor

D. Cooper, A. Carr, 1998 .

No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial *

H. Wand, A. Calmy, C. Delhumeau, 2010, HIV medicine.

Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study.

B. Hirschel, D. Cooper, A. Calmy, 2009, The Journal of infectious diseases.

Evaluation of the HIV Lipodystrophy Case Definition in a Placebo-Controlled, 144-Week Study in Antiretroviral-Naive Adults

D. Cooper, M. Law, R. Puls, 2005, Antiviral Therapy.

An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score.

M. Law, A. Carr, 2003, Journal of acquired immune deficiency syndromes.

Approaches to the management of antiretroviral therapy toxicity

O. Vujovic, A. Carr, 2009 .

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, The lancet. HIV.

Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults

J. Gatell, P. Cahn, C. Workman, 2008, AIDS.

Skeletal Muscle Toxicity Associated With Raltegravir-Based Combination Antiretroviral Therapy in HIV-Infected Adults

D. Marriott, J. Amin, S. Pett, 2013, Journal of acquired immune deficiency syndromes.

Methodological Considerations in Human Studies of Gene Expression in HIV-Associated Lipodystrophy

D. Cooper, A. Kelleher, P. Mallon, 2005, Antiviral therapy.

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment

C. Fichtenbaum, H. Stellbrink, M. Saag, 2016, AIDS.

Currently available medications in resource-rich settings may not be sufficient for lifelong treatment of HIV

David P. Wilson, K. Petoumenos, M. Boyd, 2013, AIDS.

Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study

D. Cooper, S. Emery, C. Ringland, 2004, AIDS.

Randomized, open-Label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: The OzCombo 2 study

M. Law, S. Emery, J. Amin, 2002, HIV clinical trials.

Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV

S. Kerr, E. Martinez, P. Ebeling, 2018, AIDS.

Recommendations for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Antipneumocystis Prophylaxis in Patients with Human Immunodeficiency Virus Infection.

James R. Allen, J. Phair, R. Chaisson, 1993, Journal of acquired immune deficiency syndromes.

Treatment strategies for HIV lipodystrophy

A. Carr, 2007, Current opinion in HIV and AIDS.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

David A. Cooper, D. Cooper, D. Chisholm, 1998, AIDS.

Progression of Lipodystrophy (LD) with Continued Thymidine Analogue Usage: Long-Term Follow-Up from a Randomized Clinical Trial (The PIILR Study)

S. Mallal, D. Cooper, M. Law, 2004, HIV clinical trials.

Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves lipoatrophy but compromises antiviral control: the PIILR extension study.

D. Cooper, M. Law, Allison Martin, 2002, AIDS.

Gap between biology and reality in AIDS

D. Cooper, A. Carr, 1998, The Lancet.

Abnormal fat distribution and use of protease inhibitors

D. Cooper, D. Chisholm, K. Samaras, 1998, The Lancet.

Portal vein thrombosis in patients receiving indinavir, an HIV protease inhibitor.

D. Cooper, A. Carr, D. Brown, 1997, AIDS.

Predictors of progression in long-term nonprogressors. Australian Long-Term Nonprogressor Study Group.

J. Kaldor, D. Cooper, M. Law, 1998, AIDS research and human retroviruses.

Bone turnover markers in HIV disease.

S. Emery, A. Carr, H. Haskelberg, 2011, AIDS reviews.

Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.

D. Cooper, R. Guy, P. Read, 2018, The lancet. HIV.

Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks

M. Bloch, J. Hoy, A. Carr, 2014, HIV medicine.

Investigating new antiretroviral combinations.

A. Carr, 2006, The Journal of infectious diseases.

Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [co

H. Wand, M. Law, S. Emery, 2007, Diabetes care.

Effects of primary HIV‐1 infection on subsets of CD4+ and CD8+ T lymphocytes

D. Cooper, J. Zaunders, R. Penny, 1995, AIDS.

HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research

R. Heaton, Danielle M. Moore, B. Brew, 2014, Journal of NeuroVirology.

Diabetes mellitus associated with pentamidine use in HIV‐infected patients

D. Chisholm, A. Carr, B. Depczynski, 1996, The Medical journal of Australia.

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome

D. Cooper, M. Law, John C. Miller, 2000, AIDS.

Allergic manifestations of human immunodeficiency virus (HIV) infection

D. Cooper, R. Penny, A. Carr, 1991, Journal of Clinical Immunology.

Immunohistological assessment of cutaneous drug hypersensitivity in patients with HIV infection

D. Cooper, E. Vasak, R. Penny, 1994, Clinical and experimental immunology.

Adverse effects of antiretroviral therapy

D. Cooper, David A Cooper, Andrew Carr, 2000, The Lancet.

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir.

D. Cooper, A. Kelleher, J. Zaunders, 1996, The Journal of infectious diseases.

A controlled trial of zidovudine in primary human immunodeficiency virus infection.

D. Hawkins, J. Saurat, T. Perneger, 1995, The New England journal of medicine.

Primary HIV Infection

D. Cooper, A. Carr, 2000 .

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Christof von Kalle, Roger Garsia, Robert Finlayson, 2009, Nature medicine.

Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy

D. Cooper, D. Marriott, E. Vasak, 1998, The Lancet.

Fumagillin for intestinal microsporidiosis.

D. Cooper, A. Carr, 2002, The New England journal of medicine.

Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission

D. Ho, D. Cooper, Tuofu Zhu, 1996, Journal of virology.

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group.

L. M. Lehman, J. Leonard, A. Hsu, 1995, The New England journal of medicine.

Human papillomavirus 16-specific T-cell responses and spontaneous regression of anal high-grade squamous intraepithelial lesions.

S. Garland, A. Kelleher, J. Zaunders, 2015, The Journal of infectious diseases.

Anal intraepithelial neoplasia and squamous cell carcinoma in HIV‐infected adults

A. Kelleher, A. Grulich, A. Kelleher, 2014, HIV medicine.

Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor

D. Cooper, A. Carr, 1997, The Lancet.

Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.

A. McNulty, A. Carr, T. Read, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral treatment interruption and loss to follow-up in two HIV cohorts in Australia and Asia: implications for 'test and treat' prevention strategy.

R. Guy, H. Wand, T. Sirisanthana, 2013, AIDS patient care and STDs.

Pathogenesis and management of HIV-associated drug hypersensitivity.

D. Cooper, A. Carr, 1995, AIDS clinical review.

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.

D. Cooper, S. Emery, J. Amin, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.

A. Winston, D. Cooper, D. Marriott, 2005, Journal of Antimicrobial Chemotherapy.

Dolutegravir with tenofovir disoproxil fumarate–emtricitabine as HIV postexposure prophylaxis in gay and bisexual men

A. McNulty, A. Carr, J. Mcallister, 2017, AIDS.

Raltegravir‐emtricitabine‐tenofovir as HIV nonoccupational post‐exposure prophylaxis in men who have sex with men: safety, tolerability and adherence

P. Read, A. McNulty, A. Carr, 2014, HIV medicine.

Lactic acidemia in infection with human immunodeficiency virus.

A. Carr, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

S. Mallal, D. Cooper, M. Law, 2001, AIDS.

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study

D. Cooper, D. Chisholm, K. Samaras, 1999, The Lancet.

Toxicity of antiretroviral therapy and implications for drug development

A. Carr, 2003, Nature Reviews Drug Discovery.

High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication.

M. Moroni, D. Cooper, P. Reiss, 1997, The Journal of infectious diseases.

Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial

A. Phillips, F. Goebel, J. Lundgren, 2008, Antiviral therapy.

Cardiovascular risk and body-fat abnormalities in HIV-infected adults.

S. Grinspoon, A. Carr, 2005, The New England journal of medicine.

A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study

D. Cooper, M. Law, S. Emery, 2000, AIDS.

Ageing and long‐term CD4 cell count trends in HIV‐positive patients with 5 years or more combination antiretroviral therapy experience

Stephen T. Wright, K. Petoumenos, M. Boyd, 2013, HIV medicine.

Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection

D. Cooper, A. Kelleher, J. Zaunders, 2000, AIDS.

Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia

A. Morey, D. Thorburn, P. Mallon, 2001, The Lancet.

CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.

D. Cooper, A. Kelleher, M. Law, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

C. Sabin, P. Sax, J. Lundgren, 2008, Circulation.

Simplification with fixed-dose Tenofovir-Emtricitabine or Abacavir-Lamivudine in treatment experienced, virologically suppressed adults with Hiv infection: combined analysis of two randomised, non-inferiority trials Bicombo and Steal

D. Cooper, S. Emery, E. Martinez, 2010 .

Role of Desensitisation for Drug Hypersensitivity in Patients with HIV Infection

A. Carr, 1997, Drug safety.

Combination antiretroviral therapy without a nucleoside reverse transcriptase inhibitor: experience from 334 patients in three cohorts

D. Cooper, M. Law, A. Calmy, 2007, HIV medicine.

Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor.

D. Cooper, A. Carr, 1998, The New England journal of medicine.

Characterization of Three nef-Defective Human Immunodeficiency Virus Type 1 Strains Associated with Long-Term Nonprogression

J. Kaldor, L. Ashton, N. Deacon, 2000, Journal of Virology.

Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV‐1 Infection: Recommendations of an International AIDS Society‐USA Panel

M. Schambelan, M. Saag, J. Currier, 2002, Journal of acquired immune deficiency syndromes.

Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy

J. Eisman, D. Cooper, A. Carr, 2001, AIDS.

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV‐infected patients

D. Cooper, C. Boucher, A. Imrie, 1996, AIDS.

HIV protease inhibitor-related lipodystrophy syndrome.

A. Carr, 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Current clinical experience with nevirapine for HIV infection.

D. Cooper, A. Carr, 1996, Advances in experimental medicine and biology.

A Phase I Study of the Pharmacokinetics and Safety of Passive Immunotherapy with Caprine Anti-HIV Antibodies, PEHRG214, in HIV-1--Infected Individuals

R. Day, S. Lewin, S. Emery, 2004, HIV clinical trials.

Long‐term survival and concomitant gene expression of ribozyme‐transduced CD4+ T‐lymphocytes in HIV‐infected patients

W. Gerlach, Lunquan Sun, J. Macpherson, 2005, The journal of gene medicine.

In vitro cytotoxicity as a marker of hypersensitivity to sulphamethoxazole in patients with HIV

D. Cooper, R. Penny, B. Tindall, 1993, Clinical and experimental immunology.

Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS.

D. Cooper, C. Swanson, R. Penny, 1993, The Journal of infectious diseases.

Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification.

A. Kelleher, J. Amin, A. Carr, 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV‐1‐infected individuals

D. Cooper, C. Duncombe, M. French, 1998, AIDS.

Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk

A. Carr, R. Richardson, Kate Sinn, 2010, AIDS.

Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group.

D. Cooper, J. Zaunders, M. Law, 1999, Journal of acquired immune deficiency syndromes.

Meaningful cognitive decline is uncommon in virally suppressed HIV, but sustained impairment, subtle decline and abnormal cognitive aging are not

B. Brew, L. Cysique, L. Mao, 2022, EClinicalMedicine.

HIV-associated neurocognitive disorder in Australia: a case of a high-functioning and optimally treated cohort and implications for international neuroHIV research

R. Heaton, Danielle M. Moore, B. Brew, 2014, Journal of NeuroVirology.

HIV, Vascular and Aging Injuries in the Brain of Clinically Stable HIV-Infected Adults: A 1H MRS Study

Caroline Rae, Lucette A. Cysique, Bruce J. Brew, 2013, PloS one.

Effects of IL‐2 therapy in asymptomatic HIV‐infected individuals on proliferative responses to mitogens, recall antigens and HIV‐related antigens

A. Kelleher, S. Emery, M. French, 1998, Clinical and experimental immunology.

Evidence for coinfection by multiple strains of human immunodeficiency virus type 1 subtype B in an acute seroconvertor

D. Ho, Steven Wolinsky, A. Carr, 1995, Journal of virology.

Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection. The Sydney Primary HIV Infection Study Group.

D. Cooper, A. Kelleher, J. Zaunders, 1998, The Journal of infectious diseases.

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group.

G. Stewart, D. Cooper, S. Emery, 1998, The Journal of infectious diseases.

Socioeconomic factors explain suboptimal adherence to antiretroviral therapy among HIV-infected Australian adults with viral suppression

J. D. de Wit, S. Kerr, L. Cysique, 2017, PloS one.

Rates of combination antiretroviral treatment change in Australia, 1997–2000

C. Moore, S. Mallal, D. Cooper, 2002 .

Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy

J. D. de Wit, L. Cysique, M. Giles, 2017, AIDS.

Trimethoprim‐sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS

R. Penny, B. Tindall, A. Carr, 1992, AIDS.

Primary infection with zidovudine-resistant human immunodeficiency virus type 1 does not adversely affect outcome at 1 year. Sydney Primary HIV Infection Study Group.

J. Kaldor, D. Cooper, C. Duncombe, 1996, The Journal of infectious diseases.

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy

David A. Cooper, Patrick W. G. Mallon, D. Cooper, 2003, AIDS.

The Natural History of Anal High-grade Squamous Intraepithelial Lesions in Gay and Bisexual Men.

S. Garland, S. Tabrizi, C. Fairley, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men.

D. Cooper, L. McHugh, S. Pett, 2013, Sexual health.

Participants' perspectives of self-collected anal cytological swabs.

D. Cooper, B. Brew, S. Pett, 2011, Sexual health.

Increased frequency of CCR‐5 Δ32 heterozygotes among long‐term non‐progressors with HIV‐1 infection

J. Kaldor, G. Stewart, D. Cooper, 1997 .

Dyslipidemia in HIV-Infected Patients

A. Carr, F. Lee, 2015 .

Efficacy and safety of rechallenge with low-dose trimethoprim-sulphamethoxazole in previously hypersensitive HIV-infected patients.

D. Cooper, R. Penny, A. Carr, 1993, AIDS.

Anti‐retroviral therapy, insulin resistance and lipodystrophy

K. Samaras, S. Gan, A. Carr, 2001, Diabetes, obesity & metabolism.

Poly‐l‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up

S. Emery, K. Petoumenos, A. Carr, 2009, HIV medicine.

A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy

D. Cooper, S. Emery, K. Petoumenos, 2007, Journal of acquired immune deficiency syndromes.

Conference Report - Management of HIV-Associated Lipoatrophy: Emerging Data in Clinical Context

A. Carr, 2007 .

Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial

D. Cooper, H. Wand, S. Emery, 2005, AIDS.

Posterior reversible encephalopathy syndrome (PRES) in an HIV-1 infected patient with disseminated varicella zoster virus: a case report

B. Brew, A. Carr, S. Sasson, 2013, BMC Infectious Diseases.

HIV-associated lipodystrophy: Description, pathogenesis, and molecular pathways

D. Cooper, P. Mallon, A. Carr, 2002, Current diabetes reports.

Antiretroviral therapy-associated hyperlipidaemia in HIV disease

V. Mooser, A. Carr, 2001, Current opinion in lipidology.

Prevalence of Metabolic Syndrome in HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy Using International Diabetes Foundation and Adult Treatment Panel III Criteria

H. Wand, M. Law, S. Emery, 2007, Diabetes Care.

Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.

David Bruce Lewis, R. Guy, P. Read, 2021, The lancet. HIV.

A longitudinal cohort study of HIV ‘treatment as prevention’ in gay, bisexual and other men who have sex with men: the Treatment with Antiretrovirals and their Impact on Positive And Negative men (TAIPAN) study protocol

J. Kaldor, D. Cooper, R. Guy, 2016, BMC Infectious Diseases.

High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE

R. Guy, A. McNulty, D. Templeton, 2018, AIDS and Behavior.

A New Method for Estimating the Incidence of Infectious Diseases.

J. Kaldor, R. Guy, M. Hellard, 2021, American journal of epidemiology.

Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral‐naïve cohort

W. El-Sadr, C. Grunfeld, C. Gibert, 2005, HIV medicine.

Statins as anti-inflammatory therapy in HIV disease?

A. Carr, 2011, The Journal of infectious diseases.

Loss to follow-up in the Australian HIV Observational Database

M. Law, K. Petoumenos, M. Giles, 2014, Antiviral therapy.

Currently available medications may not be sufficient for lifelong treatment of HIV

K. Petoumenos, M. Boyd, D. Wilson, 2012, Journal of the International AIDS Society.

A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men.

R. D'Agostino, J. Sterne, P. Whincup, 2007, International journal of epidemiology.

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

Dannae Brown, J. Kaldor, D. Cooper, 2002, AIDS.

Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy

D. Cooper, H. Wand, J. Kovacic, 2005, Antiviral therapy.

The use of a triple nucleoside‐nucleotide regimen for nonoccupational HIV post‐exposure prophylaxis

A. Winston, J. Amin, A. Carr, 2005, HIV medicine.

Should a protease inhibitor be standard of care for HIV postexposure prophylaxis?

A. Carr, J. Mcallister, 2011, AIDS (London).

The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters

Avis J. Thomas, P. Reiss, W. El-Sadr, 2010, AIDS.

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

D. Cooper, E. Kraegen, D. Chisholm, 2002, Diabetes.

Tolerability of HIV integrase inhibitors

A. Carr, F. Lee, 2012, Current opinion in HIV and AIDS.

Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, AIDS.

If it's the virus, why aren't we measuring it?

D. Cooper, S. Emery, A. Carr, 1995, The Medical journal of Australia.

Efficacy and tolerability of initial antiretroviral therapy: a systematic review

J. Amin, A. Carr, 2009, AIDS.

Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.

D. Cooper, J. Zaunders, P. Grey, 2001, The Journal of infectious diseases.

Attitudes to euthanasia and assisted suicide in a group of homosexual men with advanced HIV disease.

D. Cooper, B. Tindall, A. Carr, 1993, Journal of acquired immune deficiency syndromes.

CD4 Cell Responses to Combination Antiretroviral Therapy in Patients Starting Therapy at High CD4 Cell Counts

Stephen T. Wright, D. Cooper, M. Law, 2011, Journal of acquired immune deficiency syndromes.

The Incubation Period of Acute Retroviral Syndrome as a Multistep Process: A Parametric Survival Analysis

N. Voirin, P. Vanhems, L. Perrin, 2004, Journal of acquired immune deficiency syndromes.

Does HIV Cause Cardiovascular Disease?

D. Ory, A. Carr, 2006, PLoS medicine.

False negative HIV-1 proviral DNA polymerase chain reaction in a patient with primary infection acquired in Thailand.

D. Marriott, C. Harris, D. Cooper, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Lipodystrophy following antiretroviral therapy of primary HIV infection.

D. Cooper, M. Law, S. Emery, 2000, AIDS.

Predictors of Progression in Long-Term Nonprogressors

J. Kaldor, D. Cooper, M. Law, 1998 .

Changes in mitochondrial DNA in peripheral blood mononuclear cells from HIV-infected patients with lipoatrophy randomized to receive abacavir.

S. Lewin, D. Cooper, S. Wesselingh, 2004, The Journal of infectious diseases.

Transmission of triple‐class, drug‐resistant HIV‐1 in Australia

A. Kelleher, P. White, A. Carr, 2010, Internal medicine journal.

Visceral and Subcutaneous Adiposity Measurements in Adults: Influence of Measurement Site

W. El-Sadr, B. Grund, K. Ellis, 2007, Obesity.

Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction.

D. Cooper, A. Kelleher, S. Emery, 2008, The Journal of infectious diseases.

Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial

E. Martinez, M. Bloch, J. Hoy, 2016, HIV medicine.

Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

K. Ensrud, A. Schwartz, B. Grund, 2015, HIV medicine.

Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy

M. Johnson, B. Grund, R. Colebunders, 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study

J. Kaldor, K. Petoumenos, A. Pedrana, 2023, The Lancet HIV.

Vaccine-preventable anal human papillomavirus in Australian gay and bisexual men

S. Garland, S. Tabrizi, C. Fairley, 2017, Papillomavirus research.

Participants' perspectives of high resolution anoscopy.

D. Cooper, B. Brew, S. Pett, 2011, Sexual health.

Asymptomatic myocardial ischaemia in HIV-infected adults

W. El-Sadr, R. Prineas, B. Grund, 2008, AIDS.

and Relationship to Highly Active Antiretroviral Therapy Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients

C. Sabin, P. Sax, J. Lundgren, 2008 .

CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia.

D. Cooper, J. Zaunders, A. Carr, 1999, The Journal of infectious diseases.

Ability to detect high-grade squamous anal intraepithelial lesions at high resolution anoscopy improves over time.

A. Carr, R. Hillman, A. Field, 2016, Sexual health.

Financial stress is associated with reduced treatment adherence in HIV‐infected adults in a resource‐rich setting

A. Carr, J. Mcallister, E. Lavie, 2013, HIV medicine.

2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings.

B. Gazzard, R. Kaiser, B. Larder, 2021, The Journal of antimicrobial chemotherapy.

2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings

Dechao Wang, Shanmugam Saravanan, John Baxter, 2018, The Journal of antimicrobial chemotherapy.

Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.

J. Kaldor, G. Stewart, D. Cooper, 1997, AIDS.

Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection

D. Cooper, H. Wand, M. Law, 2007, AIDS.

HIV-1 DNA Is Maintained in Antigen-Specific CD4+ T Cell Subsets in Patients on Long-Term Antiretroviral Therapy Regardless of Recurrent Antigen Exposure.

D. Cooper, A. Leigh Brown, A. Kelleher, 2019, AIDS research and human retroviruses.

Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.

D. Cooper, A. Kelleher, J. Zaunders, 1999, The Journal of infectious diseases.

Socioeconomic and psychosocial factors are associated with poor treatment outcomes in Australian adults living with HIV: a case-control study.

J. D. de Wit, S. Kerr, L. Mao, 2019, Sexual health.

The role of depression chronicity and recurrence on neurocognitive dysfunctions in HIV-infected adults

B. Brew, L. Cysique, Nadene Dermody, 2016, Journal of NeuroVirology.

Additive and Synergistic Cardiovascular Disease Risk Factors and HIV Disease Markers' Effects on White Matter Microstructure in Virally Suppressed HIV.

R. Henry, C. Rae, B. Brew, 2020, Journal of acquired immune deficiency syndromes.

Characterization of the phenotypic and lymphokine profile associated with strong CD8+ anti‐HIV‐1 suppressor activity (CASA)

J. Zaunders, G. Guillemin, A. Carr, 2002, Clinical and experimental immunology.

Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy

A. Carr, 2002, The Lancet.

The CD4 cell count 3 months after acute retroviral syndrome is associated with the presence of AIDS in the source individual.

P. Vanhems, L. Perrin, B. Hirschel, 2002, AIDS (London).

The use of human immunodeficiency virus postexposure prophylaxis after successful artificial insemination.

E. Vasak, A. Carr, M. Bloch, 1999, American journal of obstetrics and gynecology.

Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV‐Infected Adults on Tenofovir: A Randomized, Open‐Label Study

S. Kerr, E. Martinez, P. Ebeling, 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Reply to Gazzola et al

A. Calmy, C. Delhumeau, A. Carr, 2010 .

Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection.

P. Vanhems, B. Hirschel, D. Cooper, 1999, Journal of acquired immune deficiency syndromes.

Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy.

D. Cooper, A. Kelleher, J. Zaunders, 2017, AIDS research and human retroviruses.

Dietary intake in HIV-infected men with lipodystrophy: relationships with body composition, visceral fat, lipid, glucose and adipokine metabolism.

D. Cooper, H. Wand, M. Law, 2009, Current HIV research.

The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection: Final Results From a Randomized Clinical Trial (Pulse)

J. Kaldor, D. Cooper, A. Kelleher, 2006, Journal of acquired immune deficiency syndromes.

Overcoming barriers to HIV pre-exposure prophylaxis (PrEP) coverage in Australia among Medicare-ineligible people at risk of HIV: results from the MI-EPIC clinical trial.

J. Amin, A. Grulich, N. Dharan, 2021, Sexual health.